Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Expected to Post Earnings of $0.29 Per Share


Share on StockTwits

Wall Street brokerages forecast that Collegium Pharmaceutical, Inc. (NASDAQ:COLL) will announce $0.29 earnings per share (EPS) for the current quarter, according to Zacks. Four analysts have made estimates for Collegium Pharmaceutical’s earnings, with estimates ranging from $0.25 to $0.35. Collegium Pharmaceutical posted earnings of $0.01 per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 2,800%. The firm is scheduled to announce its next earnings report on Thursday, May 6th.

On average, analysts expect that Collegium Pharmaceutical will report full year earnings of $1.64 per share for the current financial year, with EPS estimates ranging from $1.54 to $1.72. For the next financial year, analysts expect that the business will report earnings of $2.47 per share, with EPS estimates ranging from $2.31 to $2.79. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research analysts that follow Collegium Pharmaceutical.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its earnings results on Thursday, February 25th. The specialty pharmaceutical company reported $0.20 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.09). Collegium Pharmaceutical had a return on equity of 12.64% and a net margin of 5.71%.

A number of equities research analysts have commented on the company. Needham & Company LLC reiterated a “buy” rating on shares of Collegium Pharmaceutical in a research report on Tuesday, December 29th. HC Wainwright upped their price target on Collegium Pharmaceutical from $29.00 to $33.00 and gave the company a “buy” rating in a research report on Monday, January 11th. Finally, Zacks Investment Research upgraded Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Thursday, March 4th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $23.50.

In related news, EVP Shirley R. Kuhlmann sold 6,081 shares of the company’s stock in a transaction dated Wednesday, January 20th. The stock was sold at an average price of $24.45, for a total transaction of $148,680.45. Following the sale, the executive vice president now owns 102,891 shares in the company, valued at approximately $2,515,684.95. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Michael Thomas Heffernan sold 50,075 shares of the company’s stock in a transaction dated Monday, March 15th. The shares were sold at an average price of $25.30, for a total value of $1,266,897.50. Following the sale, the director now owns 7,078 shares in the company, valued at approximately $179,073.40. The disclosure for this sale can be found here. Insiders sold a total of 139,081 shares of company stock worth $3,288,498 in the last quarter. Corporate insiders own 8.08% of the company’s stock.

Several institutional investors have recently made changes to their positions in the stock. Dimensional Fund Advisors LP boosted its position in shares of Collegium Pharmaceutical by 0.7% during the 4th quarter. Dimensional Fund Advisors LP now owns 604,534 shares of the specialty pharmaceutical company’s stock valued at $12,109,000 after purchasing an additional 4,266 shares in the last quarter. UBS Asset Management Americas Inc. boosted its position in shares of Collegium Pharmaceutical by 10.2% during the 4th quarter. UBS Asset Management Americas Inc. now owns 30,434 shares of the specialty pharmaceutical company’s stock valued at $610,000 after purchasing an additional 2,822 shares in the last quarter. Principal Financial Group Inc. bought a new stake in shares of Collegium Pharmaceutical during the 4th quarter valued at about $7,498,000. JPMorgan Chase & Co. boosted its position in shares of Collegium Pharmaceutical by 6.1% during the 4th quarter. JPMorgan Chase & Co. now owns 28,769 shares of the specialty pharmaceutical company’s stock valued at $576,000 after purchasing an additional 1,648 shares in the last quarter. Finally, Diametric Capital LP bought a new stake in shares of Collegium Pharmaceutical during the 4th quarter valued at about $448,000.

Shares of COLL opened at $23.29 on Monday. Collegium Pharmaceutical has a 12-month low of $15.66 and a 12-month high of $26.91. The business has a 50-day simple moving average of $24.15 and a two-hundred day simple moving average of $21.50. The company has a quick ratio of 1.01, a current ratio of 1.08 and a debt-to-equity ratio of 1.27. The stock has a market cap of $809.47 million, a PE ratio of 47.53, a PEG ratio of 0.73 and a beta of 1.27.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and misuse, including chewing, crushing, and injecting.

Recommended Story: What is a SEC Filing?

Get a free copy of the Zacks research report on Collegium Pharmaceutical (COLL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.